Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis Names New President, CEO
Dr Morrissey will replace George Scangos, who has resigned to become president and CEO of Biogen Idec. Dr Morrissey is currently working as a president of research and
Dr Morrissey will replace George Scangos, who has resigned to become president and CEO of Biogen Idec. Dr Morrissey is currently working as a president of research and
Mocon said that units in the Model 3/33 series are expected to offer automatic relative humidity (RH) capability through a new software interface which is helpful to the
Teva Pharmaceutical Industries currently has Rx approval for these products, and Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation. Allegra 180mg, 60mg, and Allegra D-12 are indicated
Sanofi-aventis is initially expected to produce oral antidiabetic and cardiovascular products in the new plant which is to be build in 35,000 square meter land. The agreement was
The payment triggers Boehringer Ingelheim’s recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials. Vitae Pharma’s 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the
Dr Schnipper brings with him 20 years of experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. He also took up responsibility for many
Burkert claimed that the hygienic design and glass-free construction of the 8201pH sensor mean that the unit is particularly suitable for use in high- end hygienic processes. Additionally,
Thermo Fisher Scientific said that the new library has been computationally engineered to build on the customer-driven features of the original Maybridge Ro3 Library, such as ‘Rule of
Merck said that the Louisiana case is the first Vioxx lawsuit brought by a state attorney general to go to trial. The case was filed by the Louisiana
The issued patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents. The phosphatidylinositol 3-kinase (PI3K)